All treatment comparisons

Treatment Comparison  ·  Reviewed by Dr. Ben Soffer, DO

Prozac vs Zoloft

The two oldest SSRIs — when to pick one over the other

TL;DR

  • Prozac (fluoxetine) and Zoloft (sertraline) are both first-generation SSRIs with comparable efficacy in major depression (50-60% response rates).
  • Prozac has the longest half-life of any SSRI (~5 days for fluoxetine plus active metabolite norfluoxetine) — much smoother discontinuation than Zoloft.
  • Zoloft has broader anxiety-spectrum FDA approvals (PTSD, OCD, panic, social anxiety) — generally preferred when anxiety is the primary indication.
  • Prozac is FDA-approved for pediatric depression (8+) and OCD (7+); Zoloft for OCD (6+). Both are evidence-based pediatric options.
  • Both can cause sexual dysfunction (30-50%), weight gain over time, and GI side effects early in treatment. Zoloft tends to be more GI-active; Prozac tends to be more activating.
  • For treatment-resistant depression after multiple SSRI trials, the mechanism-switch to ketamine produces faster and more decisive answers than another within-class try.

Side by side

Prozac

Fluoxetine

SSRI (selective serotonin reuptake inhibitor)

What it treats

Major depression, OCD, Bulimia nervosa, Panic disorder, PMDD (as Sarafem)

Mechanism

Blocks serotonin reuptake at SERT. Long half-life (1-3 days fluoxetine + 5-13 days active metabolite norfluoxetine) creates a self-tapering effect that smooths discontinuation.

Strengths

  • Longest half-life of any SSRI — minimal discontinuation syndrome
  • FDA-approved for bulimia nervosa (only SSRI with this indication)
  • Pediatric depression and OCD approvals
  • Activating effect can help low-energy presentations

Limitations

  • Activation can worsen anxiety or insomnia in early weeks
  • Drug interactions via CYP2D6 inhibition
  • Long half-life means switching to MAOIs requires 5+ week washout
  • Sexual dysfunction (30-50%)

Zoloft

Sertraline

SSRI (selective serotonin reuptake inhibitor)

What it treats

Major depression, PTSD, OCD, Panic disorder, Social anxiety disorder, PMDD

Mechanism

Blocks serotonin reuptake at SERT with mild dopamine reuptake inhibition at higher doses. Half-life ~26 hours — shorter than Prozac, longer than Effexor.

Strengths

  • Strongest SSRI evidence in anxiety-spectrum disorders
  • Pregnancy safety data among the best of SSRIs
  • Mild dopaminergic effect at higher doses may help anhedonia
  • Broader anxiety FDA approvals than Prozac

Limitations

  • GI side effects (diarrhea, nausea) more common than Prozac
  • More discontinuation symptoms than Prozac (still milder than SNRIs)
  • Sexual dysfunction (30-50%)
  • Titration needed (start 25-50mg, increase weekly)

Which one for your situation?

If:

PTSD, panic disorder, or social anxiety as primary diagnosis

Verdict:

Zoloft — strongest evidence in these specific indications

If:

Bulimia nervosa or eating disorder spectrum

Verdict:

Prozac — only SSRI FDA-approved for bulimia

If:

Pregnant or planning pregnancy

Verdict:

Zoloft — most pregnancy data among SSRIs

If:

Patient with low energy / anhedonia

Verdict:

Prozac (activating) or Zoloft at higher dose (mild dopaminergic effect) — both reasonable; SSRI is sometimes the wrong class, consider Wellbutrin

If:

Patient who may struggle with consistent daily dosing

Verdict:

Prozac — long half-life makes missed doses much more forgiving

If:

After two adequate SSRI trials without response

Verdict:

Treatment-resistant — class-switch (SNRI or NDRI) or mechanism-switch (ketamine) higher-yield than another SSRI

Where ketamine fits

After two failed SSRI trials, the technical definition of treatment-resistant depression applies. Ketamine's NMDA/glutamate mechanism is entirely different from serotonin reuptake — a meaningful mechanism switch with strong evidence in treatment-resistant cases.

Prozac and Zoloft both take 4-6 weeks for full antidepressant effect. Sublingual ketamine produces measurable mood improvement within hours of the first session.

Check eligibility for ketamine therapy

5-minute screening · Reviewed by a board-certified physician · FL & NJ

Frequently asked

Which has more side effects?

Roughly comparable overall, but the profiles differ. Zoloft tends to cause more GI side effects (diarrhea, nausea) early in treatment. Prozac tends to be more activating — can worsen anxiety or insomnia in the first few weeks. Sexual dysfunction and weight gain are similar across both (30-50% rates).

Why does Prozac get prescribed for kids more often?

Prozac's long half-life smooths out daily dosing inconsistencies — important for pediatric populations. It has the most evidence in pediatric depression and is the most-prescribed SSRI for children. Zoloft is also a common pediatric option and is FDA-approved for OCD in ages 6+.

Can I switch from Prozac to Zoloft directly?

Yes, but Prozac's long half-life makes the switch self-tapering — fluoxetine and norfluoxetine remain in your system for weeks after stopping. Switching to Zoloft typically involves starting low (25mg) and titrating up while Prozac washes out. Switching to MAOIs requires a 5-week washout.

I've tried both — what's next?

After two SSRIs without adequate response, treatment-resistant depression criteria apply. Options: class-switch (SNRI like Effexor/Cymbalta, NDRI like Wellbutrin), augmentation (lithium, atypical antipsychotic), TMS, or ketamine. Ketamine has the strongest evidence in the treatment-resistant subset and works on a completely different mechanism.

Can I take ketamine while on Prozac or Zoloft?

In most cases, yes. SSRIs and sublingual ketamine work through different mechanisms (serotonin reuptake vs NMDA/glutamate) and are generally compatible. There's no requirement to taper off the SSRI before starting ketamine. Your physician reviews your full medication list during consultation to confirm no contraindications.

References

  1. Cipriani A et al. 2018, Lancet. Network meta-analysis ranking 21 antidepressants — fluoxetine and sertraline both ranked in the top efficacy tier with comparable response rates. PMID 29477251
  2. Murrough JW et al. 2013, American Journal of Psychiatry. Ketamine RCT in treatment-resistant depression — 64% response vs 28% placebo, providing a mechanism switch option after SSRI failures. PMID 23982301

Other treatment comparisons